See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
Research article
Weijia Liao
Corresponding Author
ORCiD: https://orcid.org/0000-0002-8906-8612
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Microvascular invasion (MVI) is an independent risk factor for poor prognosis in hepatocellular carcinoma (HCC). However, there is still a lack of preoperative markers to predict MVI in HCC. This study intends to explore the potential application value of the gamma-glutamyl transpeptidase (GGT) to lymphocyte count ratio (GLR) in predicting MVI in HCC and provide guidance for clinical diagnosis and treatment.
Methods: From March 2010 to December 2015, 230 HCC patients who underwent surgical treatment in the Affiliated Hospital of Guilin Medical University were selected. Clinicopathological parameters between the MVI group (n = 115) and the non-MVI group (n = 115) were comparatively analyzed. The GLR was used as the potential risk factor for HCC with MVI, and its optimal cut-off value was estimated by using the receiver operating characteristic (ROC) curve. The Kaplan-Meier method was used to analyze the survival of HCC patients, and univariate and multivariate Cox regression analyses were used to establish independent predictors affecting postoperative HCC patients.
Results: The GLR levels in the MVI group and non-MVI group were 84.83 ± 61.84 and 38.42 ± 33.52 (p < 0.001), respectively. According to ROC curve analysis, the optimal cut-off value of GLR was 56.0, and the area under the ROC curve (AUC) was 0.781 (95% CI, 0.719-0.833) for the risk prediction of MVI in HCC patients. Multivariate analysis showed that tumor size > 5 cm, HCC combined with MVI and GLR > 56.0 were independent risk factors for poor prognosis in HCC patients. In addition, compared with the non-MVI group, patients in the MVI group had shorter progression-free survival (PFS) and overall survival (OS).
Conclusion: GLR could be a predictive biomarker of HCC after operation and a potential predictor of HCC combined with MVI.
Keywords: Hepatocellular carcinoma, Microvascular invasion, GLR, Predictive
Keywords
Hepatocellular carcinoma, Microvascular invasion, GLR, Predictive
Figure 1
Figure 2
Figure 3
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
Version 3
Posted 11 Feb, 2020
No community comments so far
Editorial decision: Accept
On 11 Feb, 2020
Editor assigned
On 10 Feb, 2020
Submission checks complete
On 09 Feb, 2020
Editor invited
On 09 Feb, 2020
No comments provided
Editorial decision: Minor revision
On 06 Feb, 2020
Review #3 received
Received 02 Feb, 2020
Editor assigned
On 21 Jan, 2020
Review #2 received
Received 21 Jan, 2020
Reviewers invited
Invitations sent on 21 Jan, 2020
Reviewer #1 agreed
On 21 Jan, 2020
Reviewer #2 agreed
On 21 Jan, 2020
Reviewer #3 agreed
On 21 Jan, 2020
Reviewer #4 agreed
On 21 Jan, 2020
Review #1 received
Received 21 Jan, 2020
Submission checks complete
On 20 Jan, 2020
Editor invited
On 20 Jan, 2020
No comments provided
Review #2 received
Received 30 Dec, 2019
Editorial decision: Major revision
On 30 Dec, 2019
Review #3 received
Received 26 Dec, 2019
Review #4 received
Received 26 Dec, 2019
Review #1 received
Received 17 Dec, 2019
Reviewer #4 agreed
On 13 Dec, 2019
Reviewer #5 agreed
On 13 Dec, 2019
Reviewer #3 agreed
On 12 Dec, 2019
Reviewer #2 agreed
On 10 Dec, 2019
Reviewer #1 agreed
On 07 Dec, 2019
Editor assigned
On 05 Dec, 2019
Reviewers invited
Invitations sent on 05 Dec, 2019
Submission checks complete
On 04 Dec, 2019
Editor invited
On 02 Dec, 2019
First submitted
On 28 Nov, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Learn more about our company.
A new preprint design is coming!
We have improved readability, clarity, accessibility, and opportunities for engagement.
See the published version of this preprint at BMC Cancer.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research article
Weijia Liao
Corresponding Author
ORCiD: https://orcid.org/0000-0002-8906-8612
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at BMC Cancer.
Version 3
Posted 11 Feb, 2020
No community comments so far
Editorial decision: Accept
On 11 Feb, 2020
Editor assigned
On 10 Feb, 2020
Submission checks complete
On 09 Feb, 2020
Editor invited
On 09 Feb, 2020
No comments provided
Editorial decision: Minor revision
On 06 Feb, 2020
Review #3 received
Received 02 Feb, 2020
Editor assigned
On 21 Jan, 2020
Review #2 received
Received 21 Jan, 2020
Reviewers invited
Invitations sent on 21 Jan, 2020
Reviewer #1 agreed
On 21 Jan, 2020
Reviewer #2 agreed
On 21 Jan, 2020
Reviewer #3 agreed
On 21 Jan, 2020
Reviewer #4 agreed
On 21 Jan, 2020
Review #1 received
Received 21 Jan, 2020
Submission checks complete
On 20 Jan, 2020
Editor invited
On 20 Jan, 2020
No comments provided
Review #2 received
Received 30 Dec, 2019
Editorial decision: Major revision
On 30 Dec, 2019
Review #3 received
Received 26 Dec, 2019
Review #4 received
Received 26 Dec, 2019
Review #1 received
Received 17 Dec, 2019
Reviewer #4 agreed
On 13 Dec, 2019
Reviewer #5 agreed
On 13 Dec, 2019
Reviewer #3 agreed
On 12 Dec, 2019
Reviewer #2 agreed
On 10 Dec, 2019
Reviewer #1 agreed
On 07 Dec, 2019
Editor assigned
On 05 Dec, 2019
Reviewers invited
Invitations sent on 05 Dec, 2019
Submission checks complete
On 04 Dec, 2019
Editor invited
On 02 Dec, 2019
First submitted
On 28 Nov, 2019
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at BMC Cancer.
Background: Microvascular invasion (MVI) is an independent risk factor for poor prognosis in hepatocellular carcinoma (HCC). However, there is still a lack of preoperative markers to predict MVI in HCC. This study intends to explore the potential application value of the gamma-glutamyl transpeptidase (GGT) to lymphocyte count ratio (GLR) in predicting MVI in HCC and provide guidance for clinical diagnosis and treatment.
Methods: From March 2010 to December 2015, 230 HCC patients who underwent surgical treatment in the Affiliated Hospital of Guilin Medical University were selected. Clinicopathological parameters between the MVI group (n = 115) and the non-MVI group (n = 115) were comparatively analyzed. The GLR was used as the potential risk factor for HCC with MVI, and its optimal cut-off value was estimated by using the receiver operating characteristic (ROC) curve. The Kaplan-Meier method was used to analyze the survival of HCC patients, and univariate and multivariate Cox regression analyses were used to establish independent predictors affecting postoperative HCC patients.
Results: The GLR levels in the MVI group and non-MVI group were 84.83 ± 61.84 and 38.42 ± 33.52 (p < 0.001), respectively. According to ROC curve analysis, the optimal cut-off value of GLR was 56.0, and the area under the ROC curve (AUC) was 0.781 (95% CI, 0.719-0.833) for the risk prediction of MVI in HCC patients. Multivariate analysis showed that tumor size > 5 cm, HCC combined with MVI and GLR > 56.0 were independent risk factors for poor prognosis in HCC patients. In addition, compared with the non-MVI group, patients in the MVI group had shorter progression-free survival (PFS) and overall survival (OS).
Conclusion: GLR could be a predictive biomarker of HCC after operation and a potential predictor of HCC combined with MVI.
Keywords: Hepatocellular carcinoma, Microvascular invasion, GLR, Predictive
Figure 1
Figure 2
Figure 3
Loading...